Document Detail


Balancing risks and benefits of therapy for patients with favorable-risk limited-stage hodgkin lymphoma: the role of Doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.
MedLine Citation:
PMID:  24287067     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Because long-term survival of patients with nonbulky stage IA to IIA Hodgkin lymphoma is dependent on disease control and avoidance of late toxic effects associated with the treatment received, the initial choice of treatment can be associated with trade-offs that balance optimum disease control with avoidance of these late effect risks. Health professionals and patients face the dilemma of making treatment decisions without the benefit of completely understanding the risk-benefit balances associated with how current treatments affect all outcomes of interest. Optimum management of these patients requires careful multidisciplinary evaluation and communication strategies that account for patient preferences.
Authors:
Annette E Hay; Ralph M Meyer
Related Documents :
2293857 - Lymphocytic infiltration in uveal malignant melanoma.
23210497 - Atypical spitz tumour with positive sentinel lymph node.
19303137 - Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal strom...
16101197 - Effects of imatinib mesylate on adenoid cystic carcinomas.
21484047 - Prognostic factors of a good response to initial therapy in children and adolescents wi...
697617 - Aqueous humor lactate dehydrogenase in retinoblastoma patients. clinicopathologic corre...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hematology/oncology clinics of North America     Volume:  28     ISSN:  1558-1977     ISO Abbreviation:  Hematol. Oncol. Clin. North Am.     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2013-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709473     Medline TA:  Hematol Oncol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  49-63     Citation Subset:  IM    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Affiliation:
NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combination chemoradiotherapy in early hodgkin lymphoma.
Next Document:  Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma.